Michael Alexander Smith net worth and biography

Michael Smith Biography and Net Worth

VP of Insmed

Michael Alexander Smith is the Sr. VP & Gen. Counsel at Insmed Inc.

What is Michael Alexander Smith's net worth?: The estimated net worth of Michael Alexander Smith is at least $4.78 million as of September 13th, 2024. Mr. Smith owns 67,856 shares of Insmed stock worth more than $4,779,777 as of December 21st. This net worth approximation does not reflect any other assets that Mr. Smith may own. Learn More about Michael Alexander Smith's net worth.
How do I contact Michael Alexander Smith?: The corporate mailing address for Mr. Smith and other Insmed executives is 700 US Highway 202/206, Bridgewater NJ, 08807. Insmed can also be reached via phone at 908-977-9900 and via email at [email protected]. Learn More on Michael Alexander Smith's contact information.
Has Michael Alexander Smith been buying or selling shares of Insmed?: Michael Alexander Smith has not been actively trading shares of Insmed within the last three months. Most recently, Michael Alexander Smith sold 27,871 shares of the business's stock in a transaction on Friday, September 13th. The shares were sold at an average price of $74.35, for a transaction totalling $2,072,208.85. Following the completion of the sale, the insider now directly owns 67,856 shares of the company's stock, valued at $5,045,093.60. Learn More on Michael Alexander Smith's trading history.
Who are Insmed's active insiders?: Insmed's insider roster includes Roger Adsett (COO), Sara Bonstein (CFO), David Brennan (Director), Martina Flammer (Insider), William Lewis (CEO), Orlov Nicole Schaeffer (Insider), Melvin Sharoky (Director), Michael Smith (VP), and John Wise (Insider). Learn More on Insmed's active insiders.
Are insiders buying or selling shares of Insmed?: In the last year, insiders at the biopharmaceutical company sold shares 25 times. They sold a total of 534,475 shares worth more than $24,993,111.53. The most recent insider tranaction occured on December, 19th when CEO William Lewis sold 18,750 shares worth more than $1,310,812.50. Insiders at Insmed own 4.6% of the company. Learn More about insider trades at Insmed.
Information on this page was last updated on 12/19/2024.

Michael Alexander Smith Insider Trading History at Insmed

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/13/2024	Sell	27,871	$74.35	$2,072,208.85	67,856
1/9/2024	Sell	2,373	$28.76	$68,247.48	86,364
1/5/2024	Sell	627	$29.30	$18,371.10	88,737
7/11/2023	Sell	740	$20.18	$14,933.20	77,142
1/10/2023	Sell	1,836	$17.93	$32,919.48	54,332
1/5/2023	Sell	720	$19.72	$14,198.40	49,836
7/12/2022	Sell	941	$23.40	$22,019.40	50,455
1/11/2022	Sell	407	$25.11	$10,219.77
1/5/2022	Sell	749	$27.61	$20,679.89

Michael Alexander Smith Buying and Selling Activity at Insmed

Insmed Company Overview

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Today's Range

Now: $70.44

$68.80

$71.07

50 Day Range

MA: $72.36

$66.29

$76.65

2 Week Range

Now: $70.44

$21.92

$80.53

Volume

5,932,421 shs

Average Volume

2,217,081 shs

Market Capitalization

$12.60 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.1

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minutes of stepping into the Oval Office...

I put all the details together for you here — but please hurry.